An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology "

Table of Contents

Introduction

Part 1 - France

• Current Situation
• Respondent Population France
• Nucleic Acid Based Testing
• Genetic Testing - Routine or Research
• HPV Testing
• Oncology Markers
  • Solid Tumor Marker
  • Lymphoid Tumour Marker
• Nucleic Acid Sample Preparation
• Trends in NA-Based Oncology Diagnostics
  • Emerging Markers
  • CE approval
• NAT - application and technical appraisal
• Politics and Reimbursement
  • Drivers of NAT
  • Restraints on NAT
• Summary and Conclusions

Part 2 - Germany

• Current Situation
• Respondent Population Germany
• Nucleic Acid Based Testing
• Genetic Testing - Routine or Research
• HPV Testing
• Oncology Markers
  • Solid Tumor Marker
  • Lymphoid Tumor Marker
• Nucleic Acid Sample Preparation
• Trends in Genetics Based Oncology Diagnostics
  • Emerging Markers
  • CE certification
• NAT - application and technical appraisal
• Politics and Reimbursement
  • Drivers of NAT
  • Restraints on NAT
• Summary and Conclusions

Part 3 - Italy

• Current Situation
• Respondent Population - Italy
• Nucleic Acid Based Testing
  • Types of testing performed
• Genetic Testing - Routine or Research
• HPV Testing
• Oncology Markers
  • Solid Tumor Marker
  • Lymphoid Tumor Marker
• Nucleic Acid Sample Preparation
• Trends in NA-Based Oncology Diagnostics
• Emerging Markers
• CE or FDA approval
• NAT - application and technical appraisal
• Politics and Reimbursement
  • Drivers of NAT
  • Restraints on NAT
• Summary and Conclusions

Part 4 - United Kingdom

• Current Situation
• Respondent Population UK
• Nucleic Acid Based Testing
• Genetic Testing - Routine or Research
• HPV Testing
• Oncology Markers
  • Solid Tumor Marker
  • Lymphoid Tumor Marker
• Nucleic Acid Sample Preparation
• Trends in NA-Based Oncology Diagnostics
  • Emerging Markers
  • CE certification
• NAT - application and technical appraisal
• Politics and Reimbursement
  • Drivers of NAT
  • Restraints on NAT
• Summary and Conclusions

Part 5 - USA

• Current Situation
• Respondent Population US
• Nucleic Acid Based Testing
  • Types of testing performed
• Genetic Testing - Routine or Research
• HPV Testing
• Oncology Markers
  • Solid Tumor Marker
  • Lymphoid Tumor Marker
• Nucleic Acid Sample Preparation
• Trends in NA-Based Oncology Diagnostics
  • Emerging Marker
  • Test Certification
• NAT - application and technical appraisal
• Politics and Reimbursement
  • Drivers of NAT
  • Restraints on NAT
• Summary and Conclusions